Lakefront Biotherapeutics (LKFT) Non-Current Deffered Revenue (2016 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Non-Current Deffered Revenue for 10 consecutive years, with $758.2 million the latest figure, recorded in Q3 2025.

• Quarterly Non-Current Deffered Revenue fell 25.72% year-over-year to $758.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $758.2 million (down 25.72% YoY) and the FY2024 annual result came in at $954.6 million, down 21.69% from the prior year.
• Non-Current Deffered Revenue retreated to $758.2 million in Q3 2025 per LKFT's latest filing, from $823.7 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for LKFT reached as high as $2.4 billion in Q2 2021 and fell as low as $758.2 million in Q3 2025.
• A 5-year average of $1.4 billion and a median of $1.2 billion in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue dropped 11.28% — and 2023, when it sank 34.02%.
• Year by year, Non-Current Deffered Revenue stood at $2.2 billion in 2021, then retreated by 16.52% to $1.8 billion in 2022, then sank by 34.02% to $1.2 billion in 2023, then fell by 21.69% to $954.6 million in 2024, then retreated by 20.57% to $758.2 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $758.2 million, $823.7 million, and $889.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.